Skip to main
RGEN
RGEN logo

Repligen (RGEN) Stock Forecast & Price Target

Repligen (RGEN) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 40%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Repligen has demonstrated robust financial performance, with total orders increasing by 11% year-over-year in 4Q24, showcasing strong demand across its product categories, particularly in chromatography and capital equipment. The company achieved a notable revenue growth projection of 9.9% for 2025, supported by significant gains in CDMO and equipment sales, which exhibited sequential revenue increases of 20% and 30% respectively. Furthermore, Repligen successfully expanded its adjusted gross margin by 140 basis points in 2024 while implementing effective cost controls, positioning itself for sustained profitability and operational efficiency.

Bears say

Repligen faces a negative outlook due to several fundamental challenges impacting its financial performance, including a slowdown in purchasing from small biotech companies, which threatens revenue stability within a key customer segment. The company has experienced eroded visibility regarding customer inventory levels and spending plans, leading to a reduced order book and the subsequent downgrading of revenue expectations twice in 2024. Additionally, the transition of the well-regarded CEO Tony Hunt to Executive Chair introduces uncertainty, further exacerbating concerns over potential revenue slowdowns and fluctuations in the company's trading multiples.

Repligen (RGEN) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 40% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Repligen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Repligen (RGEN) Forecast

Analysts have given Repligen (RGEN) a Buy based on their latest research and market trends.

According to 20 analysts, Repligen (RGEN) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $161.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $161.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Repligen (RGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.